key: cord-0810486-7dy416gk
authors: Lam, Brandon; Kung, Yu Jui; Lin, John; Tseng, Ssu-Hsueh; Tsai, Ya Chea; He, Liangmei; Castiglione, Gianni; Egbert, Emily; Duh, Elia J.; Bloch, Evan M.; Tobian, Aaron A.R.; Milstone, Aaron M.; Roden, Richard B.S.; Wu, T. C.; Hung, Chien-Fu
title: In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential
date: 2021-10-05
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109838
sha: 8e80d749a73f21195945e40e48a4a2050f5ad07d
doc_id: 810486
cord_uid: 7dy416gk

As SARS-CoV-2 spreads, variants with enhanced virulence and transmissibility have emerged. While in vitro systems allow for rapid characterization, they do not fully recapitulate the dynamic interaction of virions and neutralizing antibodies in the airway. Here, we demonstrate that the N501Y variant permits respiratory infection in unmodified mice. We utilize N501Y to survey in vivo pseudovirus infection dynamics and susceptibility to reinfection with the L452R (Los Angeles), K417N + E484K (South Africa), and L452R + K417N + E484Q (India) variants. Human COVID-19+ or vaccinated antibody isotypes, titers, variant RBD binding, and neutralization potential are studied, revealing numerous significant correlations. Immune escape of the K417N + E484K variant is observed, as infection can be appreciated in the nasopharynx, but not lungs, of mice transferred with low antibody-tier plasma. Conversely, near-complete protection is observed in the animals receiving high antibody-tier plasma, a phenomenon that can only be appreciated in vivo.

The heightened infectivity and rechallenge susceptibility mediated by K417N Fig. 4f-h) . This trend held for all 3 SARS-CoV-2 PsVs and was further confirmed when 232 analyzing neutralization ability versus antibody level ( Fig. 4i-k) . Reciprocal log 10 IC50 values 233 between high-tier COVID-19 patients and high-tier vaccinated individuals were comparable 234 ( Fig. 4f-h) , suggesting that both possess high neutralization abilities. When examining the ability 235 of COVID-19+ and vaccinated individuals to neutralize South Africa N501Y + K417N + E484K 236 + D614G VsV PsVs compared to N501Y + D614G VsV PsVs, markedly lower reciprocal 237 log 10 IC50 values were noted for the South Africa N501Y + K417N + E484K + D614G variant, 238 suggesting that it was not neutralized as efficiently as the N501Y + D614G variant (Fig. 4g) . 239

This decrease in neutralization ability was not observed for the Los Angeles N501Y + L452R + 240 D614G variant (Fig. 4h) . Individual neutralization curves for each plasma sample and variant 241

PsV combination were also determined ( Supplementary Fig. 4 ). Similar findings were observed 242 for murine SARS-CoV-2 anti-sera ( Supplementary Fig. 6a-f) . 243

We wanted to explore factors beyond titer that could be contributing mechanistically to 246 the immune escape seen with South Africa N501Y + K417N + E484K + D614G PsVs in the 247 presence of COVID-19+ and vaccinated individuals plasma samples. First, we measured IgG 248 antibody levels that specifically bind WT RBD vs N501Y + K417N + E484K + D614G variant 249 RBD. This varies from total anti-Spike antibodies, as RBD-directed antibodies would contribute 250 significantly more to the observed differential neutralization and immune escape. While the same 251 titer trends remained for WT IgG RBD-directed responses compared to anti-Spike, a significant 252 ablation of binding was observed for IgGs against N501Y + K417N + E484K + D614G RBD 253 (Fig. 4l, Supplementary Fig. 5a ). This trend appeared even stronger for low-mid tier groups in 254 J o u r n a l P r e -p r o o f COVID-19+ patients. High-tier COVID-19+ and vaccinated individuals plasma samples still 255 suffered from a decrease in N501Y + K417N + E484K + D614G RBD IgG levels, but it was not 256 as pronounced. We extended this study to anti-SARS-CoV-2 RBD IgM (Fig. 4l ,m, 257 Supplementary Fig. 5b) and IgA (Fig. 4l,n, Supplementary Fig. 5c ) titers. While present, less 258 pronounced anti-WT RBD levels were seen between each tier group for both IgM system allow for seamless measurement of infection using optical imaging. Conversely, the 327 downside of PsV application in vivo is that they limit the ability to study tissue damage and 328 murine transmission which theoretically could be studied using viable SARS-CoV-2. 329

There are many potential explanations for the lower infectivity observed for the Los 330

Angeles Variant, including the theory that L452R drives enhanced transmissibility, but not 331 necessarily infectivity. This is further supported by our study regarding infectivity of PsVs 332 incorporating mutations found in the India variant, as the L452R mutation was also present and 333 did not mediate an enhancement of infection compared to the South Africa variant PsV. In our studies, Lenti-or VsV-based SARS-CoV-2 PsVs are used to model COVID-19 382 ( Fig. 1) . We demonstrate that VsV-based PsVs are significantly more infective, and 383 consequently use them for our detailed in vivo studies ( Fig. 1-6 ). The biggest advantage of using 384

PsVs for these studies is that they allow for experiments to be conducted in BSL2 conditions, 385 significantly reducing cost and occupational hazards. BSL2 conditions also simplify the ability 386 for other groups to reproduce our system in various lab environments. However, this system 387 brings with it many limitations including lack of spread, a single round of infection, and inability 388 to model clinical pathogenesis of SARS-CoV-2. Accordingly, our data ( 

The authors have declared that no competing interests exists. 417

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in 419 science. While citing references scientifically relevant for this work, we also actively worked to 420 promote gender balance in our reference list. Further requests for information for reagents should be directed to Dr. Chien-Fu Hung 594 (chung2@jhmi.edu), our lead contact, and they will be fulfilled within reasonable request. 595

Plasmids generated that were used for PsV production are available upon request. Their 597 production method has been provided in the manuscript. There are no other new materials 598 generated in this manuscript. 599

Data and code availability: 600  All data reported in this paper will be shared by the lead contact upon request. 601  This paper does not report original code. 602  Any additional information required to reanalyze the data reported in this paper is 603 available from the lead contact upon request. 604 

Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera 861 from individuals vaccinated with Pfizer vaccine BNT162b2

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus 931 by BNT162b2 vaccine-elicited human sera

Neutralization of SARS-CoV-2 lineage B.1.1.7 934 pseudovirus by BNT162b2 vaccine-elicited human sera

Animal models for 937 COVID-19

Comparative Performance of Five Commercially 940

Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with 941 High Neutralizing Titers

Spike mutation D614G alters SARS-CoV-2 944 fitness

Eicosanoid signaling as a therapeutic 947 target in middle-aged mice with severe COVID-19

Resurgence 950 of COVID-19 in Manaus, Brazil, despite high seroprevalence

Cell entry 952 mechanisms of SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

A Comprehensive Review of Animal Models for Coronaviruses: SARS-CoV-957 2, SARS-CoV, and MERS-CoV

IgA dominates the early neutralizing antibody response 960 to SARS-CoV-2

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and 963 Treatment

D614G, N501Y + L452R + D614G, or N501Y + K417N +E484K + D614G PsVs were treated 773 intranasally in a volume of 50ul, followed by 30uL of PBS wash intranasally. For blocking 774 experiments, normal or COVID 19+ human plasma was purchased from Stem Cells and 775RayBiotech. RBD-Fc mouse plasma was taken from RBD-Fc vaccinated mice which were 776 treated intranasally with 2 doses of 30ug RBD-Fc and 5ug of MPL 2-weeks apart. and boiled at 100°C for 5 minutes. Proteins were separated on 4-15% Tris-glycine SDS-PAGE 806 gels, stained with Coomassie blue at room temperature for 1 hour, and de-stained with water at 807 room temperature overnight. Images were collected on a chemidoc (BioRad) 808